Article Details

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab ...

Retrieved on: 2023-01-12 22:04:24

Tags for this article:

Click the tags to see associated articles and topics

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab .... View article details on HISWAI: https://pipelinereview.com/index.php/2023011282479/Antibodies/Zenas-BioPharma-Announces-First-Patient-Dosed-in-Phase-3-Clinical-Study-of-Obexelimab-for-the-Treatment-of-Immunoglobulin-G4-Related-Disease-IgG4-RD.html

Excerpt

WALTHAM, MA, USA I January 11, 2023 I Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up